pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

70 catalysts · 19 phase 2 completion · 9 phase 2 initiation · 9 phase 1 completion · 8 phase 1 initiation · 8 phase 0 trial completion · 5 phase 1 2 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 0 catalysts2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
TA: multiple-sclerosis×TA: pain×TA: cardiology×TA: dermatology×clear all
type
  • phase 2 completion19
  • phase 2 initiation9
  • phase 1 completion9
  • phase 1 initiation8
  • phase 0 trial completion8
  • phase 1 2 completion
5
  • constraining patent expiry europe2
  • phase 3 initiation2
  • pdufa1
  • patent expiry1
  • therapy area
    • Oncology127
    • Infectious Disease38
    • Cardiology36
    • Immunology28
    • Dermatology26
    • Pulmonology18
    • Women's Health15
    • Ophthalmology14
    • Pain11

    Week of Apr 20, 2026

    9
    ›Apr 26, 2026constraining patent expiry europe91d agoBlue Blood Biotech Corp — BB-101 (Constraining Patent Expiry (Europe))BB-101

    Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

    full page →BB-101 →source: globaldata
    ›Apr 26, 2026patent expiry91d agoBlue Blood Biotech Corp — BB-101 (Constraining Patent Expiry (Japan))BB-101

    Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

    full page →BB-101 →source: globaldata
    ›Apr 26, 2026phase 1 2 completion91d agoMahatma Gandhi Ayurved College Hospital and research centre — ayurvedic medicine (Phase I/II Trial Completion)ayurvedic medicine

    Therapy area: Cardiovascular. Indication: Thrombophlebitis

    full page →ayurvedic medicine →source: globaldata
    ›Apr 26, 2026phase 2 completion91d agoChongqing Jinsaixing Medical Technology Co Ltd — Neauvia Intense (Phase II Trial Completion)Neauvia Intense

    Therapy area: Dermatology. Indication: Wrinkles

    full page →Neauvia Intense →source: globaldata
    ›Apr 26, 2026phase 2 initiation91d agoTianFang Pharmaceutical Co — diclofenac sodium DR (Phase II Trial Initiation)DICLOFENAC SODIUM

    Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Dental Pain (Toothache/Tooth Pain), Dysmenorrhea, Gouty Arthritis (Gout), Injury, Myalgia (Muscle Pain), Osteoarthritis, Pain, Post-Operative Pain, Rheumatic Disorders, Rheumatoid Arthritis, Spondyloarthritis (Spondyloarthropathy), Tenosynovitis

    full page →DICLOFENAC SODIUM →source: globaldata
    ›Apr 26, 2026phase 2 initiation91d agoChittagong Medical College — difelikefalin (Phase II Trial Initiation)difelikefalin

    Therapy area: Dermatology, Genito Urinary System. Indication: Chronic Kidney Disease (Chronic Renal Failure), Pruritus

    full page →difelikefalin →source: globaldata
    ›Apr 26, 2026phase 2 results91d agoMinistry of Education University and Research, Italy — artichoke (Phase II Trial Results)artichoke

    Therapy area: Cardiovascular, Gastrointestinal. Indication: Endothelial Dysfunction, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)

    full page →artichoke →source: globaldata
    ›Apr 26, 2026phase 3 completion91d agoTehran University of Medical Sciences — diltiazem (Phase III Trial Completion)diltiazem

    Therapy area: Cardiovascular. Indication: Unspecified Cardiovascular Disorders

    full page →diltiazem →source: globaldata
    ›Apr 26, 2026phase iii iv trial completion91d agoRajaRajeswari Medical College & Hospital — stromal vascular fraction (Phase III/IV Trial Completion)stromal vascular fraction

    Therapy area: Dermatology. Indication: Androgenic Alopecia

    full page →stromal vascular fraction →source: globaldata

    Week of Apr 27, 2026

    41
    ›Apr 27, 2026pdufa90d agoRegeneron Pharmaceuticals Inc — dupilumab (PDUFA)dupilumab

    Therapy area: Dermatology. Indication: Chronic Urticaria

    full page →dupilumab →source: globaldata
    ›Apr 27, 2026phase 1 initiation
    ← prev
    page 1 of 2
    next →
    90d ago
    BrainBees Solutions Ltd — Babyhug pro soothing relief diaper rash cream (Phase I Trial Initiation)Babyhug pro soothing relief diaper rash cream

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →Babyhug pro soothing relief diaper rash cream →source: globaldata
    ›Apr 27, 2026phase 2 initiation90d agoTianjin Lisheng Pharmaceutical Co Ltd — aminophylline (Phase II Trial Initiation)aminophylline

    Therapy area: Cardiovascular, Respiratory. Indication: Asthma, Bronchitis, Emphysema, Pulmonary Edema

    full page →aminophylline →source: globaldata
    ›Apr 27, 2026phase 2 initiation90d agoBrainBees Solutions Ltd — Babyhug pro soothing relief diaper rash cream (Phase II Trial Initiation)Babyhug pro soothing relief diaper rash cream

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →Babyhug pro soothing relief diaper rash cream →source: globaldata
    ›Apr 27, 2026phase 2 initiation90d agoMahatma Gandhi Medical College and Hospital — rosuvastatin (Phase II Trial Initiation)rosuvastatin

    Therapy area: Cardiovascular. Indication: Acute Coronary Syndrome, Myocardial Infarction

    full page →rosuvastatin →source: globaldata
    ›Apr 27, 2026phase 2 initiation90d agoYichun Maternal and Child health Care Hospital — sufentanil (Phase II Trial Initiation)sufentanil

    Therapy area: Central Nervous System, Women's Health. Indication: Labor And Delivery, Pain

    full page →sufentanil →source: globaldata
    ›Apr 27, 2026phase 2 initiation90d agoCentral South University Xiangya Hospital 3 — HRS-2129 (Phase II Trial Initiation)HRS-2129

    Therapy area: Central Nervous System. Indication: Pain

    full page →HRS-2129 →source: globaldata
    ›Apr 27, 2026phase 2 initiation90d agoAlfred Health Victoria — amiodarone (Phase II Trial Initiation)amiodarone

    Therapy area: Cardiovascular. Indication: Atrial Fibrillation, Congestive Heart Failure (Heart Failure)

    full page →amiodarone →source: globaldata
    ›Apr 27, 2026phase 2 3 initiation90d agoKLES Dr Prabhakar Kore Hospital & Medical Research Centre — esmolol (Phase II/III Trial Initiation)esmolol

    Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

    full page →esmolol →source: globaldata
    ›Apr 27, 2026phase 3 initiation90d agoSun Pharmaceutical Industries Ltd — ruxolitinib (Phase III Trial Initiation)ruxolitinib

    Therapy area: Dermatology. Indication: Vitiligo

    full page →ruxolitinib →source: globaldata
    ›Apr 27, 2026phase 3 initiation90d agoSiriraj Hospital — tranexamic acid (Phase III Trial Initiation)tranexamic acid

    Therapy area: Cardiovascular, Dermatology. Indication: Melasma (Chlosma), Venous Thromboembolism

    full page →tranexamic acid →source: globaldata
    ›Apr 28, 2026phase 1 completion89d agoInternational Bio Service Co Ltd — Bisoprolol fumarate (Phase I Trial Completion)BISOPROLOL FUMARATE

    Therapy area: Cardiovascular. Indication: Hypertension

    full page →BISOPROLOL FUMARATE →source: globaldata
    ›Apr 28, 2026phase 1 completion89d agoBio-Innova Co Ltd — clarithromycin (Phase I Trial Completion)clarithromycin

    Therapy area: Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genito Urinary System, Infectious Disease, Mouth and Dental Disorders, Respiratory. Indication: Abscess, Acne Vulgaris, Acute Bacterial Sinusitis, Acute Bronchitis, Acute Pharyngitis, Bacterial Pneumonia, Bacterial Respiratory Tract Infections, Bartonella Infections, Bronchitis, Carbuncle, Cellulitis, Chlamydia trachomatis Pneumonia, Chronic Bronchitis, Community Acquired Pneumonia, Community-Acquired

    full page →clarithromycin →source: globaldata
    ›Apr 28, 2026phase 1 completion89d agoPolfa Tarchomin SA — empagliflozin (Phase I Trial Completion)SYNJARDY

    Therapy area: Cardiovascular, Metabolic Disorders. Indication: Congestive Heart Failure (Heart Failure), Type 2 Diabetes

    full page →SYNJARDY →source: globaldata
    ›Apr 28, 2026phase 1 initiation89d agoVirginia Commonwealth University — fluorouracil (Phase I Trial Initiation)Efudex

    Therapy area: Dermatology. Indication: Burns

    full page →Efudex →source: globaldata
    ›Apr 28, 2026phase 2 completion89d agoUniversity of Sao Paulo General Hospital — iloprost (Phase II Trial Completion)iloprost

    Therapy area: Cardiovascular. Indication: Pulmonary Arterial Hypertension

    full page →iloprost →source: globaldata
    ›Apr 28, 2026phase iv trial initiation89d agoRajendra Institute of Medical Sciences — levobupivacaine (Phase IV Trial Initiation)levobupivacaine

    Therapy area: Central Nervous System. Indication: Pain

    full page →levobupivacaine →source: globaldata
    ›Apr 29, 2026phase 1 completion88d agoUniversity of Washington — autologous mitochondria (Phase I Trial Completion)autologous mitochondria

    Therapy area: Cardiovascular. Indication: Cerebrovascular Disease, Ischemia

    full page →autologous mitochondria →source: globaldata
    ›Apr 29, 2026phase 1 initiation88d agoBayer AG — asundexian (Phase I Trial Initiation)asundexian

    Therapy area: Cardiovascular. Indication: Ischemic Stroke

    full page →asundexian →source: globaldata
    ›Apr 29, 2026phase 2 completion88d agoBangalore Medical College and Research Institute — dinoprostone (Phase II Trial Completion)dinoprostone ER

    Therapy area: Dermatology. Indication: Vitiligo

    full page →dinoprostone ER →source: globaldata
    ›Apr 29, 2026phase 2 initiation88d agoSawai Man Singh Medical College — phenylephrine (Phase II Trial Initiation)phenylephrine

    Therapy area: Cardiovascular. Indication: Hypotension

    full page →phenylephrine →source: globaldata
    ›Apr 29, 2026phase iii iv trial initiation88d agoChettinad Hospital and Research Institute — undisclosed local anesthesia (Phase III/IV Trial Initiation)undisclosed local anesthesia

    Therapy area: Central Nervous System. Indication: Pain

    full page →undisclosed local anesthesia →source: globaldata
    ›Apr 30, 2026constraining patent expiry europe87d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

    Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

    full page →telavancin hydrochloride →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoKunming Yan'an Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Pain

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoRuijin Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System, Dermatology. Indication: Burns, Pain, Sedation

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoCivil Aviation General Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Cardiovascular, Respiratory. Indication: Ischemia Reperfusion Injury, Lung Disease

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoShanghai Jiao Tong University — insulin (Phase 0 Trial Completion)insulin

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →insulin →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoFoundation for the Promotion of Health and Biomedical Research of Valencia — Aquacel Ag + (Phase 0 Trial Completion)Aquacel Ag +

    Therapy area: Dermatology. Indication: Pressure Ulcers

    full page →Aquacel Ag + →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoHefei First People’s Hospital — ergothioneine (Phase 0 Trial Completion)ergothioneine

    Therapy area: Cardiovascular. Indication: Atherosclerosis

    full page →ergothioneine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoKey Projects of Science and Technology Department of Sichuan Province — dantrolene (Phase 0 Trial Completion)dantrolene

    Therapy area: Cardiovascular. Indication: Ischemia, Myocardial Ischemia, Ventricular Arrhythmia

    full page →dantrolene →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoInner Mongolia Aerospace Hospital — (bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12) (Phase 0 Trial Completion)(bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12)

    Therapy area: Cardiovascular, Gastrointestinal. Indication: Atherosclerosis, Irritable Bowel Syndrome

    full page →(bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12) →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoJiangxi Jemincare Group Co Ltd — JMKX-003142 (Phase I Trial Completion)JMKX-003142

    Therapy area: Cardiovascular, Genetic Disorders. Indication: Edema, Polycystic Kidney Disease

    full page →JMKX-003142 →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoEcolab Inc — (acetaminophen + ibuprofen) (Phase I Trial Completion)(acetaminophen + ibuprofen)

    Therapy area: Central Nervous System, Ear Nose Throat Disorders, Hormonal Disorders, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Ankylosing Spondylitis (Bekhterev's Disease), Dental Pain (Toothache/Tooth Pain), Fever, Fibromyalgia (Fibromyalgia Syndrome), Gouty Arthritis (Gout), Hyperthyroidism, Laryngitis, Low Back Pain, Mixed Pain (Nociceptive Pain/Neuropathic Pain), Musculoskeletal Inflammation, Musculoskeletal Pain, Myalgia (Muscle Pain), Neuropathic Pa

    full page →(acetaminophen + ibuprofen) →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoJiangsu Postgraduate Research and Practice Innovation Program — acetaminophen (Phase I Trial Completion)acetaminophen ER

    Therapy area: Cardiovascular. Indication: Patent Ductus Arteriosus

    full page →acetaminophen ER →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoPhrae Hospital — bupivacaine (Phase I Trial Completion)bupivacaine

    Therapy area: Cardiovascular, Central Nervous System, Gastrointestinal. Indication: Hypotension, Post Operative Nausea And Vomiting, Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoBarts Charity — undisclosed Covid-19 vaccine (Phase I Trial Completion)undisclosed Covid-19 vaccine

    Therapy area: Cardiovascular. Indication: Cardiovascular Disease, Endothelial Dysfunction

    full page →undisclosed Covid-19 vaccine →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoEgyptian International Pharmaceuticals Industries Co SAE — enoxaparin sodium biosimilar (Phase I Trial Initiation)enoxaparin sodium biosimilar

    Therapy area: Cardiovascular. Indication: Acute Coronary Syndrome, Congestive Heart Failure (Heart Failure), Deep Vein Thrombosis (DVT), Myocardial Infarction, Pulmonary Embolism, Thromboembolic Disease, Thromboembolism, Thrombosis, Unstable Angina, Venous (Vein) Thrombosis, Venous Thromboembolism

    full page →enoxaparin sodium biosimilar →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoFirst Affiliated Hospital of Bengbu Medical University — Loberamisal (Phase I Trial Initiation)Loberamisal

    Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke

    full page →Loberamisal →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoJiangsu Vcare PharmaTech Co Ltd — VC-005 (Phase I Trial Initiation)VC-005

    Therapy area: Dermatology. Indication: Atopic Dermatitis (Atopic Eczema)

    full page →VC-005 →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoMerck & Co Inc — MK-6050 (Phase I Trial Initiation)MK-6050

    Therapy area: Dermatology. Indication: Hidradenitis Suppurativa

    full page →MK-6050 →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoBio-Innova Co Ltd — dapagliflozin (Phase I Trial Initiation)DAPAGLIFLOZIN

    Therapy area: Cardiovascular, Genito Urinary System, Metabolic Disorders. Indication: Cardiovascular Risk Factors, Diabetic Nephropathy, Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes

    full page →DAPAGLIFLOZIN →source: globaldata
    $REGN656.01+0.63%
    $CPIX6.6100-5.37%
    $ECL268.75+2.13%
    $MRK131.07+0.45%